Sutro Biopharma, Inc., a company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, has secured $110.0 million in new investment capital. This funding round provides substantial resources to further its mission of transforming what science can do for patients. The South San Francisco-headquartered firm is dedicated to advancing novel solutions in oncology, leveraging its proprietary technology to address critical unmet medical needs in cancer treatment.
Central to Sutro's innovative approach is its fit-for-purpose technology, notably the cell-free XpressCF® platform. This advanced technology provides the opportunity for broader patient benefit and an improved patient experience by enabling the precise design and development of complex biologics. Sutro is actively advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs). The company's continuous product innovation and strategic industry partnerships further validate its scientific platform and development capabilities.
The $110.0 million in capital raised is expected to significantly bolster Sutro Biopharma's operational capacity and accelerate its ongoing research and development initiatives. The company plans to allocate these funds towards advancing its pipeline of novel cancer therapeutics and expanding its technological capabilities to bring more innovative treatments to clinical development. This investment underscores confidence in Sutro's platform and its potential to deliver transformative solutions for patients battling cancer. Looking ahead, Sutro Biopharma aims to continue its growth trajectory, pushing the boundaries of scientific discovery to make a lasting impact in oncology.
